Which of the following medication management practices should a nurse employ when teaching patients about chemotherapy for brain cancer?

Choice A rationale Brain tumors and their subsequent treatments, including chemotherapy and radiation, significantly increase the risk of focal or generalized seizures due to cortical irritation, peritumoral edema, or changes in blood-brain barrier permeability. Levetiracetam is frequently used as a prophylactic or therapeutic agent because it has a favorable side effect profile and minimal interactions with many chemotherapy agents. Preventing seizures is a priority to maintain patient safety, prevent secondary brain injury, and improve quality of life. Choice B rationale Minimizing fluid intake is contraindicated and potentially dangerous during chemotherapy. Many chemotherapeutic agents and the breakdown of tumor cells can be nephrotoxic. Maintaining adequate hydration is essential to ensure proper renal clearance of drugs and to prevent the crystallization of metabolic byproducts in the renal tubules. While managing cerebral edema is important, dehydration can lead to hypotension, electrolyte imbalances, and increased toxicity, which can actually exacerbate headaches and other systemic side effects of the treatment. Choice C rationale Effective nursing care for brain cancer patients must be holistic, addressing both physiological and psychosocial needs. A diagnosis of brain cancer often carries a heavy emotional burden, including anxiety, depression, and fear regarding cognitive decline or personality changes. Focusing solely on the pharmacological regimen ignores the impact of the disease on the patient's mental health and social support systems. Comprehensive education should include resources for counseling and support groups to help patients navigate the complex stressors. Choice D rationale Patients should never be encouraged to discontinue prescribed medications, especially anticoagulants, without direct medical supervision. Chemotherapy and malignancy itself create a hypercoagulable state, increasing the risk of deep vein thrombosis and pulmonary embolism. Suddenly stopping blood thinners could lead to life-threatening thromboembolic events. Any adjustments to a medication regimen prior to starting chemotherapy must be coordinated by the oncology team and the prescribing physician to balance the risks of bleeding versus the risks of clotting.